India Globalization Capital Inc (IGC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, India Globalization Capital Inc (IGC) has a cash flow conversion efficiency ratio of -0.258x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.09 Million) by net assets ($8.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see India Globalization Capital Inc (IGC) market capitalisation for the company's overall valuation and market capitalisation.
India Globalization Capital Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how India Globalization Capital Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
India Globalization Capital Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of India Globalization Capital Inc ranked by their cash flow conversion efficiency. Explore India Globalization Capital Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Duxton Farms Ltd
AU:DBF
|
-0.113x |
|
Gurktaler AG ST
VI:GAGS
|
-0.006x |
|
Cobalt Blue Holdings Limited
F:COH
|
-0.018x |
|
Sc Engineering
KO:023960
|
-0.171x |
|
Geomega Resources Inc
V:GMA
|
-0.797x |
|
FN REPUBLIC Co. Ltd
KQ:064090
|
0.025x |
|
Nordic Mining ASA
OL:NOM
|
-0.088x |
|
Safari World PLC
BK:SAFARI
|
0.111x |
Annual Cash Flow Conversion Efficiency for India Globalization Capital Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of India Globalization Capital Inc from 2006 to 2025. View IGC stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $6.33 Million | $-4.79 Million | -0.758x | -6.67% |
| 2024-03-31 | $7.32 Million | $-5.20 Million | -0.710x | -50.26% |
| 2023-03-31 | $14.91 Million | $-7.05 Million | -0.473x | -51.32% |
| 2022-03-31 | $23.89 Million | $-7.46 Million | -0.312x | +5.14% |
| 2021-03-31 | $32.80 Million | $-10.80 Million | -0.329x | -0.69% |
| 2020-03-31 | $26.54 Million | $-8.68 Million | -0.327x | -229.65% |
| 2019-03-31 | $33.57 Million | $-3.33 Million | -0.099x | +58.58% |
| 2018-03-31 | $8.06 Million | $-1.93 Million | -0.239x | -26.52% |
| 2017-03-31 | $7.35 Million | $-1.39 Million | -0.189x | -1573.88% |
| 2016-03-31 | $13.95 Million | $-157.70K | -0.011x | +93.55% |
| 2015-03-31 | $14.75 Million | $-2.58 Million | -0.175x | -42.23% |
| 2014-03-31 | $14.15 Million | $-1.74 Million | -0.123x | -1134.88% |
| 2013-03-31 | $14.97 Million | $178.20K | 0.012x | +103.75% |
| 2012-03-31 | $15.82 Million | $-5.02 Million | -0.318x | +12.10% |
| 2011-03-31 | $7.29 Million | $-2.63 Million | -0.361x | -219.70% |
| 2010-03-31 | $26.15 Million | $-2.96 Million | -0.113x | +47.27% |
| 2009-03-31 | $37.86 Million | $-8.11 Million | -0.214x | -2.22% |
| 2008-03-31 | $40.87 Million | $-8.57 Million | -0.210x | -611.92% |
| 2007-03-31 | $52.92 Million | $-1.56 Million | -0.029x | -1451.85% |
| 2006-03-31 | $50.17 Million | $-95.21K | -0.002x | -- |
About India Globalization Capital Inc
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatm… Read more